Progress towards the use of Listeria monocytogenes as a live bacterial vaccine vector for the delivery of HIV antigens

Expert Review of Vaccines

Volumn 3, Issue 4 SUPPL., 2004, Pages

  Paterson, Yvonne ^a   Johnson, Ross S ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VIRGINIA STATE UNIVERSITY   (United States)

Author keywords

Antigen carrier; Cell mediated immunity; HIV vaccine; Listeria monocytogens; Listeriosis; Macaques; Mice; Mucosal immunity; Oral vaccine; Vaccine vector

Indexed keywords

BACTERIAL ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GAG PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NEF PROTEIN; PLASMID DNA; TUMOR NECROSIS FACTOR ALPHA;

CELLULAR IMMUNITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; GENETIC ENGINEERING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; LISTERIA MONOCYTOGENES; NONHUMAN; PLASMID; PRIORITY JOURNAL; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINE PRODUCTION;

ADMINISTRATION, ORAL; AIDS VACCINES; ANIMALS; HIV ANTIGENS; HUMANS; IMMUNIZATION; INJECTIONS, INTRAVENOUS; LISTERIA MONOCYTOGENES;

EID: 4344573008     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.3.4.S119     Document Type: Review

References (96)

1. Gallo RC, Montagnier L. The discovery of HIV as the cause of AIDS. N. Engl. J. Med. 349, 2283-2285 (2003).
2. Ada GL. The immunological principles of vaccination. Lancet 335, 523-526 (1990).
3. Yap KL, Ada GL, McKenzie IFC. Transfer of cytotoxic T-lymphocytes protect mice inoculated with influenza virus. Nature 273, 238-240 (1978).
4. Raychaudhuri S, Rock KL. Fully mobilizing host defense, building better vaccines. Nature Biotech. 16, 1025-1031 (1998).
5. Levy JA. Pathogenesis of human immunodeficiency virus infection. Microbiol. Rev. 57, 183-289 (1993).
6. Kou RA, Safrit JT, Cao Y et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus Type 1 syndrome. J. Virol. 68, 4650-4655 (1994).
7. Pantaleo G, Demarest JF, Schacker T et al. The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc. Natl Acad. Sci. USA 94, 234-258 (1997).
8. Ogg GS, Jin X, Bonhoeffer S et al. Quantitation of HIV-1-specific cytotoxic T-lymphocytes and plasma load of viral RNA. Science 279, 2103-2106 (1998).
9. Rowland-Jones SL, Tan R, McMchael A. Role of cellular immunity in protection against HIV infection. Adv. Immunol. 65, 277-346 (1997).
10. + lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J. Immunol. 164, 1602-1611 (2000).
11. Goulder P, Price, D, Nowak M, Rowland-Jones SL, Phillips R, McMchael A. Co-evolution of human immunodeficiency virus and cytotoxic T-lymphocyte responses. Immunol. Rev. 159, 17-29 (1997).
12. Price DA, Klenerman P, Booth BL, Phillips RE, Sewell AK. Cytotoxic T-lymphocytes, chemokines and antiviral immunity. Immunol. Today 20, 212-216 (1999).
13. Borrow P, Lewicki H, Wei X et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T-lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nature Med. 3, 205-211 (1997).
14. Rowland-Jones SL, Dong T, Karusa P et al. The role of cytotoxic T-cells in HIV infection. Dev. Biol. Stand. 92, 209-214 (1998).
15. Rowland-Jones SL, Dong T, Fowka KR et al. Cytotoxic T-cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. J. Clin. Invest. 102, 1758-1765 (1998).
16. Paul WE. Reexamining AIDS research priorities. Science 267, 633-636 (1995).
17. Weiskirch LM, Paterson Y. Listeria monocytogenes: a potent vaccine vector for neoplastic and infectious disease. Immunol. Rev. 158, 159-169 (1997).
18. Gunn GR, Zubair A, Paterson Y. Harnessing bacteria for cancer immunotherapy. In: Vaccines: Delivery Systems. Goebel W, Dietrich G (Eds), Horizon Scientific Press, USA, Chapter 14, 315-348 (2002).
19. Weiskirch LM, Paterson Y. The use of Listeria monocytogenes recombinants as vaccine vectors in infectious and neoplastic disease. In: Intracellular Bacterial Vaccine Vectors. Paterson Y (Ed.), John Wiley & Sons, Inc., NY, USA, Chapter 7, 223-259 (1999).
20. Jensen ER, Shen H, Wettstein FO, Ahmed R, Miller JF. Recombinant Listeria monocytogenes as a live vaccine vehicle and a probe for studying cell-mediated immunity. Immunol. Rev. 158, 147-157 (1997).
21. Cooper J, Walker RD. Listeriosis. Vet. Clin. North Am. Food Anim. Pract. 14, 113-125 (1998).
22. Portnoy DA, Chakraborty T, Goebel W, Cossart P. Molecular determinants of Listeria monocytogenes pathogenesis. Infect. Immun. 60, 1263-1267 (1992).
23. Crocker PR, Milon G. Macrophages in control of haematopoiesis. In: The Natural Immune System, Part II the Macrophage. Lewis CE, O'D McGhee J (Eds), Oxford University Press, Oxford, UK, 115-156 (1992).
24. Havell EA, Beretich GR, Carter PB. The mucosal phase of Listeria infection. Immunobiology 201, 164-177 (1999).
25. Lecuit M, Vandormael-Pourin S, Lefort J et al. A trangenic model for Listeriosis: Role of internalin in crossing the intestinal barrier. Science 292, 1722-1725 (2001). Explained why mice are a poor model for examining human listerial infection by the oral route. The mouse E-cadherin molecules differs from the human and guinea-pig E-cadherin in important amino acid residues that bind to the listerial invasion protein inIA.
26. Braun L, Cossart P. Interactions between Listeria monocytogenes and host mammalian cells. Microb. Infect. 2, 803-811 (2000).
27. Shen Y, Naujokas M, Park M, Ireton K. InIB-dependent internalization of Listeria is mediated by the Met receptor tyrosine kinase. Cell 103, 501-510 (2000)
28. Mackaness GB. Cellular resistance to infection. J. Exp. Med. 116, 381-390 (1962).
29. Edelson BT, Cossart P, Unanue ER. Cutting Edge: Paradigm revisited: antibody provides resistance to Listeria infection. J. Immunol. 163, 4087-4090 (1999).
30. Edelson BT, Unanue ER. Intracellular antibody neutralizes Listeria growth. Immunity 14, 503-512 (2001).
31. Manohar M, Baumann DO, Bos NA, Cebra JJ. Gut colonization of mice with actA-negative mutant of Listeria monocytogenes can stimulate a humoral mucosal immune response. Infect. Immun. 69, 3542-3549 (2001).
32. Vijh S, Pamer EG. Cell Biology and immune response to Listeria monocytogenes, an intracellular pathogen. In Intracellular Bacterial Vaccine Vectors Immunology, Cell Biology and Genetics. Paterson Y (Ed.), John Wiley & Sons Inc., NY, USA, Chapter 4 111-147 (1999).
33. Kaufmann SH. Immunity to intracellular bacteria. Ann. Rev. Immunol. 11, 129-163 (1993).
34. Lade CH, Flesh IEF, Arnoldi J, Kaufman SHE. Studies with MHC-deficient knockout mice reveal impact of both MHC I- and MHC-II-dependent T-cell responses on Listeria monocytogenes infection. J. Immunol. 153, 3116-3122 (1994).
35. Harty JT, Bevan MJ. Specific immunity to Listeria monocytogenes in the absence of IFN-γ. Immunity 3, 109-117 (1995).
36. + T-cell response to Listeria monocytogenes in the absence of perform and IFN-γ. J. Immunol. 164, 6444-6452 (2000).
37. Barry RA, Archie Bouwer HG, Clark TR, Cornell KA, Hinrichs DJ. Protection of interferon-γ knockout mice against Listeria monocytogenes challenge following intramuscular immunization with DNA vaccines encoding listeriolysin O. Vaccine 21, 2122-2132 (2003).
38. Schafer R, Portnoy DA, Brassell SA, Paterson Y. Induction of a cellular immune response to a foreign antigen by a recombinant Listeria monocytogenes vaccine. J. Immunol. 149, 53-59 (1992).
39. Ikonomidis G, Paterson Y, Kos F, Portnoy D. Delivery of a viral antigen to the class I processing and presentation pathway by L. monocytogenes. J. Exp. Med. 180, 2209-2218 (1994).
40. Shen H, Slifka MK, Matloubian M, Jensen ER, Ahmed R, Miller JF. Recombinant Listeria monocytogenes as a live vaccine vehicle for the induction of protective antiviral cell-mediated immunity. Proc. Natl Acad. Sci. USA 92, 3987-3991 (1995).
41. Gunn GR, Zubair A, Peters CH, Pan ZK, Wi TC, Paterson Y. Two L. monocytogenes vaccine vectors that express different molecular forms of HPV-16 E7 induce qualitatively different T-cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J. Immunol. 167, 6471-6479 (2001). First study to evaluate L. monocytogenes as a vector for a relevant human tumor-associated antigen. The authors show that a highly attenuated Listeria construct, that is deared in SCID mice, can induce the regression of established HPV immortalized tumors in syngeneic mice.
42. Sewell, DA, Douven D, Pan ZK, Rodriguez A, Paterson Y. Regression of HPV-positive tumors treated with a new Listeria monocytogenes vaccine. Arch. Otorhinolaryngol. 130, 92-97 (2004).
43. Mata M, Yao ZJ, Zubair A, Syres K, Paterson Y. Evaluation of a recombinant L. monocytogenes expressing an HIV protein that protects mice against viral challenge. Vaccine 19, 1435-1445 (2001). These investigator show that immunization with a Listeria monocytogenes that expresses HIV-1 Gag can protect mice against challenge with vaccinia that expresses HIV-1 Gag.
44. Dietrich G, Bubert A, Gentschev I et al. Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes. Nature Biotech. 16, 181-186 (1998).
45. Pilgrim S, Stritzker J, Schoen C et al. Bactofection of mammalian cells by Listeria monocytogenes: improvement and mechanism of DNA delivery. Gene Ther. 10, 2036-2045 (2003).
46. + T-cells in vivo: a study with the nucleoprotein of the lymphocytic chonomeningitis virus. Int. Immunol. 7, 797-805 (1995).
47. Ikonomidis G, Portnoy DA, Gerhard W, Paterson Y. Influenza-specific immunity induced by recombinant Listeria monocytogenes vaccines. Vaccine 15, 433-440 (1997).
48. Soussi N, Milon G, Colle JH, Mougneau E, Glaichenhaus N, Goossens PL. Listeria monocytogenes as a short-lived delivery system for the induction of Type 1 cell-mediated immunity against the p36/LACK antigen of Leishmania major. Infect. Immun. 68, 1498-1506 (2000).
49. Mata M, Paterson Y. Th1 T-cell responses to HIV-1 Gag protein delivered by a Listeria monocytogenes vaccine are similar to those induced by endogenous listerial antigens. J. Immunol. 163, 1449-1459 (1999).
50. Soussi N, Saklani-Jusforgues H, Colle JH, Milon G, Glaichenhaus N, Goossens PL. Effect of intragastric and ip. immunisation with attenuated and wild type LACK-expressing Listeria monocytogenes on control of murine Leishmania major infection. Vaccine 20, 2702-2712 (2002). The ability of Listeria to provide protective immunity against leishmaniasis in the susceptible BALB/c mouse is established and shown to be due to its propensity to induce strong T-helper (Th)1 responses.
51. Saklani-Jusforgues H, Fontan E, Soussi N, Milon G, Goossens PL. Enteral immunization with attenuated recombinant Listeria monocytogenes as a live vaccine vector, organ-dependent dynamics of CD4 T-lymphocytes reactive to a Leishmania major tracer epitope. Infect. Immun. 71, 1083-1090 (2003).
52. Pan ZK, Ikonomidis G, Lazenby A, Pardoll D, Paterson Y. A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Nature Med. 1, 471-477 (1995).
53. Pan ZK, Ikonomidis G, Patdoll D, Paterson Y. Regression of established tumors in mice mediated by the oral administration of a recombinant Listeria monocytogenes vaccine. Cancer Res. 55, 4776-4779 (1995).
54. Pan ZK, Weiskirch LM, Paterson Y. Regression of established B16F10 melanoma with a recombinant Listeria monocytogenes vaccine. Cancer Res. 59, 5264-5269 (1999).
55. Paglia P, Arioli I, Frahm N, Chakraborty T, Colombo MP, Guzman C. The defined attenuated Listeria monocytogenes delta mp12 mutant is an effective oral vaccine carrier to trigger a long-lasting immune response against a mouse fibrosarcoma. Eur. J. Immunol. 27, 1570-1575 (1997).
56. Peng X, Hussain SF, Paterson Y. The upregulation of cytokine secretion and co-stimulatory molecules on dendritic cells infected with two Listeria monocytogenes vaccines targeting HPV-16 E7 correlates with their ability to induce an antitumor response. J. Immunol. 172, 6030-6038 (2004).
57. Jensen ER, Selvakumar R, Shen H, Ahmed R, Wettstein FO, Miller JF. Recombinant Listeria monocytogenes vaccination eliminates papillomavirus-induced tumors and prevents papilloma formation from viral DNA. J. Virol. 71, 8467-8474 (1997).
58. Liau LM, Jensen ER, Kremen TJ et al. Tumor immunity within the central nervous system stimulated by recombinant Listeria monocytogenes vaccination. Cancer Res. 15, 2287-2293 (2002).
59. Frankel FR, Hegde S, Lieberman J, Paterson Y. Induction of cell-mediated immune responses to human immunodefiency virus Type 1 Gag protein by using Listeria monocytogenes as a live vaccine vector. J. Immunol. 155, 4775-4782 (1995).
60. d through interactions between a glutamine at P3 and pocket D. J. Immunol. 161, 2985-2993 (1998).
61. Klein MR, van Baalen CA, Holwerda AM et al. Kinetics of Gag-specific cytotoxic T-lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J. Exp. Med. 181, 1365-1372 (1995).
62. Jones DE, Elloso MM, Scott P. Host susceptibility factors to cutaneous leishmaniasis. Front Biosci. 3, D1171-D1180 (1998).
63. Friedman RS, Frankel FR, Xu Z, Lieberman J. Induction of human immunodeficiency virus (HIV)-specific CD8 T-cell responses by Listeria monocytogenes and a hyperattenuated Listeria strain engineered to express HIV antigens. J. Virol. 74, 9987-9993 (2000).
64. Thompson, RJ, Bouwer HG, Portnoy DA, Frankel FR. Pathogenicity and immunogenicity of a Listeria monocytogenes strain that requires D-alanine for growth. Infect. Immun. 66, 3552-3561 (1998).
65. + T-cells. Eur. J. Immunol. 28, 1807-1814 (1998).
66. Ogra PL, Faden H, Welliver RC. Vaccination strategies for mucosal immune responses. Clin. Microbiol. Revs. 14, 430-445 (2001).
67. Rayevskaya MV, Frankel FR. Systemic immunity and mucosal immunity are induced against human immunodeficiency virus Gag protein in mice by a new hyperattenuated strain of Listeria monocytogenes. J. Virol. 75, 2786-2791 (2001).
68. Rayevskaya M, Kushnir N, Frankel FR. Safety and immunogenicity in neonatal mice of a hyperattenuated Listeria vaccine directed against human immunodeficiency virus. J. Virol. 76, 918-22 (2002). These investigators show that it is possible to suitably attenuate Listeria so that it is safe to use as a vaccine with neonatal animals.
69. Snyder SH, Kim PM. D-amino acids as putative neurotransmitters: focus on D-serine. Neurochem. Res. 25, 553-560 (2000).
70. + X-cells in the spleen, LP, PP and MLN.
71. Novembre FJ, Saucier M, Anderson DC. Development of AIDS in a chimpanzee infected with human immunodeficiency virus Type 1. J. Virol. 71, 4086-1091 (1991).
72. Hirsch V M, Johnson PR. Pathogenic diversity of simian immunodeficiency viruses. Virus Res. 32, 183-203 (1994).
73. Letvin NL, King NW. Immunological and pathologic manifestations of the infection of rhesus monkeys with simian immunodeficiency virus of macaques. J. Acquir. Immune Defic. Synd. 3, 1023-1040 (1990).
74. Anderson DC, McClure HM. Listeriosis in Nonhuman Primates I. Jones TC, Mohr U, Hunt RD (Eds), Springer-Verlag, Berlin, Germany and NY, USA, 135-141 (1993).
75. Chalifoux LV, Hajema EM. Septicemia and meningoencephalitis caused by L. monocytogenes in a neonatal Macaca fasciluaris. J. Med. Primatol. 10, 336-339 (1981).
76. McClure HM, Brodie AR, Anderson DC, Swenson RB. Bacterial infections of non-human primates. In Primates: the Road to Self-sustaining Populations. Benirschke K (Ed.). Springer, Berlin, Germany & NY, USA, 531-556 (1986).
77. Boyer JD, Robinson TM, Maciag PC et al. DNA prime listeria boost induces a cellular immune response to SIV antigens in the rhesus macaque model that is apable of suppressing SIV239 viral replication. (Manuscript submitted). First paper to explore the ability of Listeria to induce immune responses in nonhuman primates. It shows that a prime-boost vaccine regimen using DNA priming and Listeria boosting conveys a protective advantage against SIV239 challenge. It also shows that Listeria can be administered safely to nonhuman primates.
78. Gellin BG, Broome CV. Listeriosis. JAMA 261, 1313-1320 (1989).
79. Lorber B. Listeriosis. Clin. Infect. Dis. 24, 1-11 (1997).
80. Cabanes D, Dehoux P, Dussurget O, Frangeul L, Cossart P. Surface proteins and the pathogenic potential of L. monocytogenes. Trends Microbiol. 10, 238-245 (2002).
81. Peters C, Domann E, Darbouche A, Chakraborty T, Mielke ME. Tailoring host immune responses to Listeria by manipulation of virulence genes - the interface between innate and acquired immunity. FEMS Immunol. Med. Microbiol. 35, 243-253 (2003). A thorough comparison of attenuated Listeria strains for their safety and immunogenicity.
82. Angelakopoulos H, Loock K, Sisul DM, Jensen ER, Miller JF, Hohmann EL, Safety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculation. Infect. Immun. 70, 3592-3601 (2002). First safety test in humans (volunteers) of an attenuated Listeria strain that could be a useful vaccine carrier. Little toxicity was associated with the vaccine.
83. Hone DM, Shata MT, Pascual DW, Lewis GK. Mucosal vaccination with Salmonella vaccine vectors. In: Intracellular Bacterial Vaccine Vectors. Paterson Y (Ed.), John Wikey & Sons Inc, NY, USA 171-222 (1999).
84. Autret N, Dubail I, Trieu-Cuot P, Betche P, Charbit A. Identification of new genes involved in the virulence of Listeria monocytogenes by signature-tagged transposon mutagenesis. Infect. Immun. 69, 2054-2065 (2001).
85. Sciali AR, Rarick TL. Salmonella sepsis and second trimester pregnancy loss. Obstet. Gynecol. 79, 820-821 (1992).
86. Vugia D, Hadler J, Blake P et al. Preliminary FoodNet data on the incidence of foodborne illness - selected sites, United States, 2001. MMWR Morb. Mortal. Wkly. Sep. 51, 325-329 (2002).
87. Young D, Hussell T, Dougan G. Chronic bacterial infections: living with unwanted guests. Nature Immunol. 3, 1026-1032 (2002).
88. Netea MG, Radstake T, Joosten IA. Salmonella septicemia in rheumatoid arthritis patients receiving antiTNF therapy: association with decreased interferon-γ production and Toll-like receptor 4 expression. Arthritis Rheum. 48, 1853-1857 (2003).
89. Farber JM, Peterkin PI. Listeria monocytogenes, a food-borne pathogen. Microbiol. Revs. 55, 476-511 (1991).
90. Dalton CB, Austin CC, Sobel J et al. An outbreak of gastroenteritis and fever due to Listeria monocytogenes in milk N. Engl. J. Med. 336, 100-105 (1997).
91. Blaser MJ, Newman L. A review of human salmonellosis: I. Infective dose. Rev. Infect. Dis. 4, 1096-1106 (1982).
92. Altare F, Lammas D, Revy, P et al. Inherited interleukin-12 deficiency in a child with Bacille Calmette-Guerin and Salmonella enteriditis disseminated infection. J. Clin. Invest. 102, 2035-2040 (1998).
93. Snider DE. Ethical issues in tuberculosis vaccine trials. Clin. Infect. Dis. 30, S271-S275 (2000).
94. Amaya RJ, Gardner, ES, Bettencourt, MS et al. Cutaneous complications of BCG vaccination in infants with immune disorders: two cases and a review of the literature. Ped. Derm. 18, 205-209 (2001).
95. Sumida SM, Truitt DM, Kishko MG et al. Neutralizing antibodies and CD8+ T-lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J. Virol. 78, 2666-2673 (2004)
96. Bouwer HG, Shen H, Fan X et al. Existing antilisterial immunity does not inhibit the development of a Listeria monocytogenes-specific primary cytotoxic T-lymphocyte response. Infect Immun. 67, 253-258 (1999). Demonstrates that prior exposure to mutant strains of L. monocytogenes that lack certain immunodominant epitopes does not inhibit the development of a primary CTL response to these epitopes delivered by wild-type L. monocytogenes. These results suggest that pre-existing vector immunity will not inhibit the use of L. monocytogenes as a vaccine vector.